Member Info for researcher1

well, I promised you all an RNS Monday - and we got two! - though must admit I was hoping for more than a couple of PMEs...!

yep, me too, though I'm onto T20s as out of readies....!

you may get your wish lawaccian - the omen of a 1 share deal today - reputed to mean news next day, so see you at 7am Monday....

please I picked up those extras at 80 and 81p - imagine if we get the Pharma contract news tomorrow.....

each to their own gl - I will just keep buying! £2+ per share in 6 months....

it's already there tom! (half a house sale anyway - thankfully when the SP was 40p - the other half has gone on a barn conversion...)

it is now in classic buy-back territory - I've added this month's salary....

the share price on each exchange will be linked, so there is no benefit in that sense - however there is a good chance that US investors will appreciate the opportunity, and upward pressure on the NASDAQ price will translate into upward movement on AIM. The SP is suffering today from the rise in Sterling - US investors are cashing in huge gains, both in the SP and the rate when they convert back to dollars. Many AIM shares are suffering from this syndrome today, but thankfully Angle have potent newsflow items to bring the money back....

either is technically possible Tom, but Angle have said they intend a dual listing, and have an American Depository Receipt set up already for this. What with that and the UK clinic, UK manufacturer for Parsortix, and new UK offices, in my opinion dual listing is as likely as FDA approval!

looking good here - about time the IP was recognised....

and the SP goes down - ha ha - what tricks afoot? but who cares.....

agreed skid, though the pipeline is has potential for JVs or IP sales - and then of course there are the SBTX golden tickets, which may pretty much cover the MCAP here by year end... the drop seems a bit petty and overdone...

another fantastic endorsement - I'm sure Angle is on the watchlist of many medical devices companies, jostling for position. Monday is the start of the FDA reply window, so best stock up tomorrow just in case! (though I still think April will be the month). GLA

thanks Tom - the damage explains the less reliable results - perhaps why they have disappeared somewhat. In any case, years behind Parsortix....

already added this morning Tom - I am averaging up effectively, but happy to as my portfolio is looking fairly bouncy at present.

I'm with you Chester, except that I'm prepared to buy more. Much better now than a scrabble to place orders when news drops....

a bargain - anyone tempted this morning, or are we waiting for 89p?

hi Tom, Rarecells have developed a not dissimilar approach (ISET), using a different method, and I think they may prove a competitor at clinic level (although demand will far outstrip capacity). They have not yet begun their clinical trials however, so are a good 3 years behind Angle in terms of FDA approval, and I recall the tests are more expensive and less accurate (though capable of a comparable degree of precision).

150 calendar days means we will arrive in decision territory on March 1st....

I think you are about right Buzz, and the general comments from the company have always suggested: April would be great, at the latest by June (but no guarantees). The FDA has in fact been working weekends during C-19 to expedite submissions, but it is not clear (at least to me) whether this applies to virus-related submissions only. And you are right to factor in that there will likely be some clarifications required, though hopefully very few as Angle has worked closely with FDA reps on this. I'm expecting news on the clinics and contracts will drop in the next month (beginning as early as this week), to keep us entertained until April itself, after which the share will be a pressure cooker waiting to blow its lid....